ACAD Q3 2024 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$250M+18.3% YoY

Gross Profit

$232M92.5% margin

Operating Income

$32M12.6% margin

Net Income

$33M13.1% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

$63M

Free Cash Flow

$63M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$977M

Total Liabilities

$400M

Stockholders' Equity

$577M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$250M	$212M	+18.3%
Gross Profit	$232M	$197M	+17.5%
Operating Income	$32M	-$58M	+154.8%
Net Income	$33M	-$65M	+150.3%